Study guide
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms
Key Takeaways Explain This Topic AI
Acute effects occur during or shortly after therapy and resolve, long-term effects begin during therapy and persist afterward, and late effects appear months to decades after treatment has ended.
The typical chemotherapy neutrophil nadir occurs 7 to 14 days after administration with recovery by day 21 to 28, while carboplatin causes a delayed platelet nadir around day 21.
Acute radiation toxicity affects rapidly dividing tissues within 90 days, whereas late radiation toxicity reflects fibrosis and endarteritis and appears after 90 days to years.
CTCAE version 5.0 grades adverse events from 1 (mild) to 5 (death), and grade 3 generally means severe but not immediately life-threatening, usually triggering hospitalization or treatment interruption.
Predicting the timing of a symptom is what allows prophylaxis: antiemetics before nausea, growth factors before nadir, and skin care before radiation dermatitis.
Last updated: August 2026
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms
Blueprint focus: ONCC Domain II.I — Etiology, incidence, and patterns for treatment-related symptoms (acute, late, long term). This blueprint item is about timing . Knowing when a toxicity will appear is what converts reactive management into prophylaxis.
Three Timing Categories
Category Definition Examples
Acute Occurs during or within days to weeks of treatment; resolves after the drug clears or the tissue recovers Nausea and vomiting, myelosuppression, mucositis, acute radiation dermatitis, infusion reactions, cholinergic diarrhea
Long-term (persistent) Begins during treatment and continues after it ends Chemotherapy-induced peripheral neuropathy, cancer-related fatigue, lymphedema, cognitive impairment, premature ovarian insufficiency
Late Appears months to decades after treatment has ended, in a patient who had recovered Anthracycline cardiomyopathy, radiation-induced second malignancy, radiation fibrosis, therapy-related myeloid neoplasm, hypothyroidism after neck radiation
The distinction is not academic. Acute effects are managed with prophylaxis and supportive care; long-term effects are managed with rehabilitation and adaptation; late effects require lifelong surveillance in a patient who otherwise considers themselves cured.
- Predictable Acute Timelines
- Myelosuppression
- Cell line Typical nadir Typical recovery Clinical consequence
- Neutrophils Days 7 to 14 Days 21 to 28 Febrile neutropenia risk peaks at nadir
- Platelets Days 10 to 14 Days 21 to 28 Bleeding risk
Red cells Cumulative over cycles Slow; life span roughly 120 days Anemia and fatigue accumulate rather than nadir
Important exceptions: carboplatin produces a delayed platelet nadir around day 21 with thrombocytopenia as its dose-limiting toxicity; nitrosoureas such as carmustine and lomustine produce a delayed and prolonged nadir at 4 to 6 weeks , which is why they are given every 6 weeks rather than every 3.
Growth factor timing follows from this: pegfilgrastim or filgrastim is given 24 to 72 hours after chemotherapy completion, before the nadir, and never within 24 hours of cytotoxic therapy.
Nausea and vomiting
Acute: within 24 hours of administration, peaking at 5 to 6 hours.
Delayed: after 24 hours, typically days 2 to 5, and characteristic of cisplatin, carboplatin, and anthracycline-cyclophosphamide combinations.
Anticipatory: before the next cycle, a conditioned response created by inadequate control of a prior cycle.
Breakthrough and refractory describe failure of prophylaxis during and across cycles respectively.
Diarrhea
Irinotecan early (cholinergic): during or within 24 hours, with diaphoresis, cramping, lacrimation, and salivation; treated with atropine.
Irinotecan late (secretory): after 24 hours, from the SN-38 metabolite; treated with high-dose loperamide.
Immune checkpoint inhibitor colitis: typically weeks to months after initiation, and can appear after the drug has been stopped.
Mucositis
Onset 5 to 10 days after chemotherapy, coinciding with the neutrophil nadir, and healing over 1 to 2 weeks as counts recover. With radiation, mucositis begins around the second week of treatment and peaks at completion.
Radiation
Acute (within 90 days): rapidly dividing tissues — skin, mucosa, bone marrow within the field, bowel. Erythema begins around 2 to 3 weeks; dry then moist desquamation follows.
Subacute: radiation pneumonitis typically presents 1 to 6 months after thoracic radiation.
Late (after 90 days to years): fibrosis, endarteritis obliterans, necrosis, strictures, xerostomia, lymphedema, hypothyroidism, and second malignancy.
Infusion reactions
Non-IgE cytokine or complement-mediated: during the first or second infusion, characteristic of taxanes and of monoclonal antibodies such as rituximab.
True IgE-mediated hypersensitivity: requires prior sensitization and characteristically appears after multiple cycles , classically around cycles 6 to 8 with platinum agents.
Modality-Specific Late Effects
Modality Late effect Surveillance
Anthracyclines Cardiomyopathy and heart failure, dose-dependent above roughly 450 to 550 mg/m² of doxorubicin, presenting years later Serial echocardiography; lifelong awareness
Bleomycin Pulmonary fibrosis above roughly 400 units cumulative PFTs with DLCO; avoid high FiO2 during anesthesia
Cisplatin Sensorineural hearing loss, tinnitus, chronic kidney disease, persistent neuropathy, hypomagnesemia Audiometry, renal function, magnesium
Alkylating agents Infertility, premature ovarian insufficiency, therapy-related MDS/AML at 5 to 7 years Annual CBC; endocrine and fertility follow-up
Topoisomerase II inhibitors Therapy-related AML at 1 to 3 years with KMT2A rearrangement Annual CBC
Radiation (any field) Fibrosis, second malignancy after more than 10 years, tissue-specific damage Field-specific lifelong surveillance
Neck radiation Hypothyroidism, carotid stenosis, xerostomia, dental caries, osteoradionecrosis TSH every 6 to 12 months; dental follow-up
Chest radiation Coronary disease, valvular disease, breast cancer, pulmonary fibrosis Cardiac risk management; breast MRI and mammography per Section 2.4
Pelvic radiation Infertility, sexual dysfunction, bladder and bowel toxicity, insufficiency fractures Symptom-directed
Immune checkpoint inhibitors Permanent endocrinopathy — hypothyroidism, hypophysitis, type 1 diabetes, adrenal insufficiency Lifelong hormone replacement; TSH monitoring
HSCT Chronic GVHD, secondary malignancy, endocrine failure, cataracts, avascular necrosis Transplant long-term follow-up protocols
Androgen deprivation therapy Osteoporosis, metabolic syndrome, cardiovascular risk, sarcopenia DEXA, lipids, glucose, exercise
- Aromatase inhibitors Bone loss, arthralgia DEXA every 2 years, calcium and vitamin D
- Grading With CTCAE Version 5.0
- Grade Meaning
- 1 Mild; asymptomatic or mild symptoms; observation only
2 Moderate; minimal, local, or non-invasive intervention indicated; limits instrumental activities of daily living
3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation indicated; disabling; limits self-care
- 4 Life-threatening consequences; urgent intervention indicated
- 5 Death related to the adverse event
Grading drives action. Most protocols hold therapy at grade 3 , and grade 2 immune-related adverse events already trigger corticosteroids and drug interruption. Grade the event, then apply the label's modification table — do not improvise.
Turning Timing Knowledge Into Prophylaxis
Before cycle 1, name the expected toxicities and their expected day , and give the patient a written calendar.
Prescribe prophylaxis before the symptom : guideline antiemetics for the emetogenic level, growth factors when regimen risk is 20% or more, antimicrobial prophylaxis where indicated, skin care from the first day of radiation, and bowel prophylaxis with the first opioid.
Schedule laboratory checks at the predicted nadir , not at an arbitrary interval.
Teach the specific red flags and the number to call , with fever above 38.0 to 38.3 °C as an emergency rather than a next-business-day problem.
Document toxicity by CTCAE grade so that the next clinician can apply the correct dose modification.